Business Context and Reporting Period
The filing is for Priveterra Acquisition Corp., not AEON Biopharma, Inc. It covers the period from incorporation on November 17, 2020 through December 31, 2020, with audited financial statements for that inception period. Priveterra was a blank-check company formed to complete a business combination, with an intended focus on the medical technology sector. It had not selected a target or begun substantive operating activities as of December 31, 2020.
The company subsequently completed its initial public offering on February 11, 2021. The filing refers to AEON Biopharma as an entity with which certain management personnel had affiliations, but it does not report AEON Biopharma as the registrant.
Key Financial Metrics
| Metric | Period or date | Amount |
|---|---|---|
| Revenue | Inception through December 31, 2020 | $0 |
| Formation and operating costs | Inception through December 31, 2020 | $3,588 |
| Net loss | Inception through December 31, 2020 | $3,588 |
| Cash | December 31, 2020 | $0 |
| Total assets | December 31, 2020 | $81,000 |
| Current liabilities | December 31, 2020 | $59,588 |
| Stockholders’ equity | December 31, 2020 | $21,412 |
| Operating cash flow | Inception through December 31, 2020 | $0; formation costs were funded through sponsor-related financing |
Margins, operating profitability, and meaningful year-over-year comparisons are not applicable because the company had no revenue or operating business. No cash flow from investing activities or financing activities was reported for the inception period. The company had no long-term debt, leases, or off-balance-sheet arrangements at December 31, 2020.
Material Changes and Subsequent Financing
- On February 11, 2021, Priveterra sold 27.6 million units at $10.00 per unit, generating gross proceeds of $276.0 million.
- Each unit included one Class A common share and one-third of a warrant. The public warrants had an exercise price of $11.50 per share.
- The sponsor purchased 5.213 million private placement warrants for $7.82 million.
- $276.0 million was placed in a trust account. The company reported approximately $2.577 million in its operating bank account and approximately $2.001 million of working capital after the IPO.
- IPO transaction costs totaled approximately $15.590 million, including $9.660 million of deferred underwriting fees payable only if a business combination is completed.
- On February 15, 2021, the company issued a sponsor convertible promissory note permitting borrowings of up to $1.5 million; $100,000 had been drawn as of March 19, 2021.
Guidance, Outlook, Risks, and Unusual Items
Management expected to incur significant public-company, diligence, and transaction expenses while searching for a target. The company did not provide revenue, earnings, or operating guidance. Its ability to continue depended on completing a business combination or obtaining additional sponsor financing.
- The company was required to complete an initial business combination within 24 months of the IPO, generally by February 11, 2023, or redeem the public shares and liquidate.
- Public stockholders received redemption rights at approximately $10.00 per share, subject to trust-account performance, taxes, creditor claims, and the requirement that net tangible assets remain at least $5.000 million.
- If no transaction was completed, public warrants would expire worthless and the sponsor’s founder shares and private placement warrants would also be at risk of becoming worthless.
- Third-party creditor claims, bankruptcy, negative interest rates, or an inability of the sponsor to satisfy its indemnification obligations could reduce the amount available to public stockholders.
- Founder shares represented 20% of common stock after the IPO and would convert into Class A shares upon a business combination, subject to anti-dilution provisions that could increase dilution.
- Management and directors had outside fiduciary, contractual, and business commitments, creating potential conflicts in identifying and selecting a target. The filing also disclosed noncompetition restrictions involving certain personnel.
- COVID-19 was identified as a potential adverse factor, although its specific financial impact was not determinable.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2020. No auditor attestation was required because the company was an emerging growth company.
Most Important Facts to Verify
- Confirm the correct registrant: the supplied filing is for Priveterra Acquisition Corp. and does not constitute an AEON Biopharma, Inc. 10-K.
- Verify whether the requested filing period and company name were mismatched in the source metadata.
- For Priveterra, verify completion status and terms of any subsequent business combination, redemption activity, extensions, liquidation, or changes in trust-account balances.
- Review sponsor ownership, founder-share conversion and anti-dilution provisions, private placement warrants, and potential dilution from working-capital loans.
- Assess trust-account protections, deferred underwriting fees, creditor claims, sponsor indemnification capacity, and the risk that redemption proceeds could be below $10.00 per share.